Mycobacteriophage D29: A tool for TB diagnosis

Mycobacteriophages are viruses that infect mycobacterium species. They were initially found approximately 72 years ago. Around 25211 Mycobacteriophages have been isolated to date, with 4284 mycobacteriophage genomes sequenced. Phage research contributed significantly to our understanding of mycobacteria in the 1960s and 1970s and the development of typing processes widely used in tuberculosis epidemiological studies. After the development of various antibiotics, phage research has received little attention. With the rise in antibiotic resistance while treating tuberculosis and millions of deaths from tuberculosis, phages have refocused everyone’s attention on the viable treatment of tuberculosis. The increasing prevalence and mortality rate of tuberculosis has led researchers to delve deeper into mycobacteriophage research. The potential of phage D29 as a diagnostic reagent is now being realized as a better candidate for quick bacterial detection, drug susceptibility testing, investigating phage biology, and as tools in recombinant DNA technology are being developed, thereby aiding the investigation of mycobacterial pathogenesis. This review encapsulates mycobacteriophage D29's current landscape and future prospects, emphasizing genetic and clinical applications that could revolutionize tuberculosis management. By fostering the development of cost-effective diagnostic tools and contributing to therapeutic strategies, mycobacteriophage D29 becomes a pivotal asset in the ongoing battle against tuberculosis.